Compare Stocks: NKTR, CYTK, PTGX, and PCVX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$72.09	$80.12	$35.22 ▼ $88.31	$8.97B	0.39	1.93 million shs	4.36 million shs
NKTR Nektar Therapeutics	$72.52	$70.94	$27.87 ▼ $109.00	$2.48B	1.14	579,580 shs	579,654 shs
PCVX Vaxcyte	$59.83 0.0%	$57.48	$30.32 ▼ $65.00	$8.90B	1.23	920,019 shs	759,733 shs
PTGX Protagonist Therapeutics	$144.33	$138.51	$54.50 ▼ $160.81	$9.34B	1.78	493,390 shs	500,143 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-6.18%	-6.53%	-2.16%	+104.05%
NKTR Nektar Therapeutics	0.00%	-2.03%	+2.62%	+13.56%	+142.87%
PCVX Vaxcyte	0.00%	-4.46%	+10.63%	+22.33%	+94.32%
PTGX Protagonist Therapeutics	0.00%	-6.47%	+5.63%	+52.05%	+144.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$72.09	$80.12	$35.22 ▼ $88.31	$8.97B	0.39	1.93 million shs	4.36 million shs
NKTR Nektar Therapeutics	$72.52	$70.94	$27.87 ▼ $109.00	$2.48B	1.14	579,580 shs	579,654 shs
PCVX Vaxcyte	$59.83 0.0%	$57.48	$30.32 ▼ $65.00	$8.90B	1.23	920,019 shs	759,733 shs
PTGX Protagonist Therapeutics	$144.33	$138.51	$54.50 ▼ $160.81	$9.34B	1.78	493,390 shs	500,143 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-6.18%	-6.53%	-2.16%	+104.05%
NKTR Nektar Therapeutics	0.00%	-2.03%	+2.62%	+13.56%	+142.87%
PCVX Vaxcyte	0.00%	-4.46%	+10.63%	+22.33%	+94.32%
PTGX Protagonist Therapeutics	0.00%	-6.47%	+5.63%	+52.05%	+144.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.86	Moderate Buy	$102.20	41.77% Upside
NKTR Nektar Therapeutics	2.77	Moderate Buy	$141.50	95.12% Upside
PCVX Vaxcyte	2.50	Moderate Buy	$86.00	43.74% Upside
PTGX Protagonist Therapeutics	2.94	Moderate Buy	$140.53	-2.63% Downside

Current Analyst Ratings Breakdown

Latest NKTR, CYTK, PTGX, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	NKTR Nektar Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	NKTR Nektar Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
8/17/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$112.00 ➝ $178.00
8/14/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$95.00 ➝ $110.00
8/13/2026	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$97.00 ➝ $103.00
8/12/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	PTGX Protagonist Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/10/2026	PTGX Protagonist Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $170.00
8/10/2026	CYTK Cytokinetics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$106.00 ➝ $112.00
8/10/2026	PTGX Protagonist Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$118.00 ➝ $173.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$88.04M	101.89	N/A	N/A	($5.39) per share	-13.37
NKTR Nektar Therapeutics	$55.23M	44.83	N/A	N/A	$4.41 per share	16.44
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
PTGX Protagonist Therapeutics	$46.02M	202.95	N/A	N/A	$9.83 per share	14.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	140.13	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)

Latest NKTR, CYTK, PTGX, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	6.66	6.66
NKTR Nektar Therapeutics	N/A	10.42	10.42
PCVX Vaxcyte	N/A	5.72	5.72
PTGX Protagonist Therapeutics	N/A	21.71	21.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
NKTR Nektar Therapeutics	75.88%
PCVX Vaxcyte	96.78%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.60%
NKTR Nektar Therapeutics	2.50%
PCVX Vaxcyte	3.30%
PTGX Protagonist Therapeutics	5.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	124.43 million	121.20 million	Optionable
NKTR Nektar Therapeutics	220	34.14 million	33.29 million	Optionable
PCVX Vaxcyte	160	148.80 million	143.89 million	Optionable
PTGX Protagonist Therapeutics	120	64.71 million	61.35 million	Optionable

NKTR, CYTK, PTGX, and PCVX Headlines

Recent News About These Companies

Wellington Management Group LLP Sells 182,863 Shares of Protagonist Therapeutics, Inc. $PTGX

August 30 at 5:36 AM | marketbeat.com

Hsbc Holdings PLC Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX

August 30 at 5:04 AM | marketbeat.com

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Alyeska Investment Group L.P.

August 30 at 3:04 AM | marketbeat.com

US FDA approves drug for rare blood cancer

August 29 at 12:47 PM | msn.com

58,059 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Twin Lakes Capital Management LLC

August 29 at 6:23 AM | marketbeat.com

The Manufacturers Life Insurance Company Purchases Shares of 108,555 Protagonist Therapeutics, Inc. $PTGX

August 29 at 5:31 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Acquires New Shares in Protagonist Therapeutics, Inc. $PTGX

August 29 at 4:16 AM | marketbeat.com

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

August 28 at 8:30 PM | accessnewswire.comA

Bamco Inc. NY Makes New $1.96 Million Investment in Protagonist Therapeutics, Inc. $PTGX

August 28 at 3:27 AM | marketbeat.com

Bank of New York Mellon Corp Purchases New Position in Protagonist Therapeutics, Inc. $PTGX

August 28 at 3:20 AM | marketbeat.com

Seven Fleet Capital Management LP Purchases 41,400 Shares of Protagonist Therapeutics, Inc. $PTGX

August 27, 2026 | marketbeat.com

9,414 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by J. Goldman & Co LP

August 27, 2026 | marketbeat.com

Artia Global Partners LP Takes $2.81 Million Position in Protagonist Therapeutics, Inc. $PTGX

August 27, 2026 | marketbeat.com

Jupiter Topco LLC Takes $261.04 Million Position in Protagonist Therapeutics, Inc. $PTGX